In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other, and you, the reader, will determine the winner.
Today it's the Semi-Final stage, and Seadrill takes on Isis Pharmaceuticals in our search for the better stock.
Joel South, energy analyst at The Motley Fool, thinks Seadrill (NYSE: SDRL) is more than worthy of your consideration today. Successful investors have been building significant wealth for years by finding solid, high dividend paying stocks. Seadrill sports an industry leading 10% yield and with solid contract coverage and a fleet of new drilling rigs, investors can count on Seadrill to be among the best offshore drillers in the world.
David Williamson, Motley Fool health care analyst, thinks Isis Pharmaceuticals (NASDAQ:IONS) should advance to the next round because of one big reason -- its amazing drug pipeline. Wall Street heralds it as the best in biotech and puts Isis in play as a takeover target. A virtual who's who of big pharma has struck partnership deals. Isis already has orphan drug Kynamro on the market, and has seen recent success from a mid-stage study for an anti-clotting drug. A recent sell-off has given investors a chance to get this deep pipeline at a discounted price.
Vote here to determine the winner of this match and sound off in the comments box below. Check back to Fool.com to see who advances in the final.
David Williamson has no position in any stocks mentioned. Joel South has no position in any stocks mentioned. The Motley Fool recommends Isis Pharmaceuticals and Seadrill. The Motley Fool owns shares of Seadrill. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.